Lavaca Capital’s Pfizer PFE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $262K | Sell |
10,873
-394
| -3% | -$10.3K | 0.03% | 113 |
|
|
2026
Q1 | $316K | Buy |
11,267
+639
| +6% | +$17K | 0.06% | 85 |
|
|
2025
Q4 | $265K | Buy |
10,628
+1,267
| +14% | +$32K | 0.04% | 90 |
|
|
2025
Q3 | $239K | Buy |
9,361
+20
| +0.2% | +$494 | 0.04% | 94 |
|
|
2025
Q2 | $226K | Buy |
9,341
+20
| +0.2% | +$466 | 0.08% | 97 |
|
|
2025
Q1 | $236K | Sell |
9,321
-182
| -2% | -$4.76K | 0.1% | 93 |
|
|
2024
Q4 | $252K | Sell |
9,503
-2,477
| -21% | -$67.2K | 0.1% | 104 |
|
|
2024
Q3 | $347K | Buy |
11,980
+416
| +4% | +$12.1K | 0.15% | 82 |
|
|
2024
Q2 | $324K | Buy |
11,564
+316
| +3% | +$8.7K | 0.17% | 68 |
|
|
2024
Q1 | $312K | Buy |
11,248
+601
| +6% | +$16.7K | 0.18% | 65 |
|
|
2023
Q4 | $307K | Sell |
10,647
-3,240
| -23% | -$97.9K | 0.17% | 74 |
|
|
2023
Q3 | $461K | Sell |
13,887
-710
| -5% | -$25.1K | 0.15% | 102 |
|
|
2023
Q2 | $535K | Sell |
14,597
-11,451
| -44% | -$446K | 0.16% | 105 |
|
|
2023
Q1 | $1.11M | Buy |
26,048
+241
| +0.9% | +$10.4K | 0.23% | 69 |
|
|
2022
Q4 | $1.26M | Buy |
25,807
+10,605
| +70% | +$508K | 0.39% | 56 |
|
|
2022
Q3 | $760K | Buy |
15,202
+8
| +0.1% | +$389 | 0.27% | 82 |
|
|
2022
Q2 | $750K | Buy |
15,194
+8
| +0.1% | +$408 | 0.11% | 108 |
|
|
2022
Q1 | $786K | Sell |
15,186
-21,125
| -58% | -$1.1M | 0.08% | 130 |
|
|
2021
Q4 | $2.14M | Sell |
36,311
-6,900
| -16% | -$342K | 0.28% | 37 |
|
|
2021
Q3 | $1.86M | Sell |
43,211
-2,275
| -5% | -$101K | 0.19% | 36 |
|
|
2021
Q2 | $1.78M | Sell |
45,486
-21,984
| -33% | -$855K | 0.18% | 33 |
|
|
2021
Q1 | $2.44M | Buy |
67,470
+12,378
| +22% | +$439K | 0.21% | 23 |
|
|
2020
Q4 | $2.03M | Buy |
55,092
+15,138
| +38% | +$555K | 0.27% | 26 |
|
|
2020
Q3 | $1.39M | Buy |
39,954
+5,933
| +17% | +$208K | 0.22% | 35 |
|
|
2020
Q2 | $1.05M | Buy |
34,021
+5,042
| +17% | +$171K | 0.34% | 35 |
|
|
2020
Q1 | $897K | Hold |
28,979
| – | – | 0.87% | 26 |
|
|
2019
Q4 | $1.08M | Hold |
28,979
| – | – | 0.83% | 28 |
|
|
2019
Q3 | $988K | Hold |
28,979
| – | – | 0.75% | 33 |
|
|
2019
Q2 | $1.19M | Sell |
28,979
-527
| -2% | -$20.9K | 0.92% | 28 |
|
|
2019
Q1 | $1.19M | Hold |
29,506
| – | – | 1.01% | 25 |
|
|
2018
Q4 | $1.22M | Buy |
+29,506
| New | +$1.22M | 1.22% | 22 |
|
Other funds holding PFE
Lavaca Capital's PFE Position: Q2 2026 in Review
Lavaca Capital reduced its Pfizer (PFE) stake by 3.5% in Q2 2026, selling an estimated $10.3K and leaving 10,873 shares worth $262K. The position accounts for 0.03% of the portfolio, ranked #113.
Lavaca Capital first reported a position in PFE in Q4 2018 and has held it in 31 quarters since. The position peaked at $2.44M in Q1 2021. 2,834 funds tracked by Wall St. Rank hold PFE as of Q2 2026.
- Lavaca Capital held 10,873 shares of Pfizer worth $262K as of Q2 2026.
- Lavaca Capital sold 394 Pfizer shares in Q2 2026, an estimated $10.3K.
- Pfizer made up 0.03% of Lavaca Capital's portfolio in Q2 2026, its #113 holding.
- Lavaca Capital first reported a position in Pfizer in Q4 2018 and has held it in 31 quarters since.
- Lavaca Capital's Pfizer position peaked at $2.44M in Q1 2021.
- 2,834 funds tracked by Wall St. Rank held Pfizer as of Q2 2026.
Based on Lavaca Capital's 13F filing for Q2 2026, filed 14 Aug 2026.